Skip to content

New Strategy to Predict Early Sepsis

Development of a New Strategy to Predict Early Sepsis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04118179
Enrollment
1000
Registered
2019-10-08
Start date
2018-08-01
Completion date
2023-07-31
Last updated
2023-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

This is an observational prospective multicentre study on patients attending the emergency department and suspected to have sepsis. Blood markers characteristic of a Cellular Reprogramming (CR) signature and predicting severe sepsis and organ failure will be measured and validated.

Detailed description

Sepsis is a life-threatening medical condition caused by an infection and the complex and dysfunctional way by which the human body attempts to deal with it. It can affect people of all ages, causing 18-30 million cases and 5-8 million deaths annually worldwide. However, early diagnosis of sepsis is challenging due to the diversity and overlap of symptoms with other disorders and the lack of an early and accurate diagnostic method. Hancock and colleagues defined a gene expression signature characteristic of biological changes occurring during sepsis, known as cellular reprogramming (CR) and reflecting a type of immune amnesia (inability to respond to bacterial signals). This signature was shown to predict the development of sepsis and organ failure at first clinical presentation in the emergency room, by examining patient blood samples taken during an initial pilot single-center study. This project will validate and refine the CR signature and demonstrate reproducibility, specificity, and sensitivity in a larger multi-center study to enable a new strategy to predict Sepsis.

Interventions

OTHERBlood sample collection

A blood sample (1 tube) will be collected for the analysis of the CR signature.

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
University of British Columbia
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female * Presenting to the Emergency Department * Attending physician suspects possible sepsis based on at least 2 sign of Systemic inflammatory response syndrome (SIRS) criteria and suspicion of infection

Exclusion criteria

* Patient is terminal (death anticipated in 12 hours) * Informed consent unobtainable if the subject survives to hospital discharge. * Subjects who are unable to provide blood as a standard of care. * Blood sample could not be taken within 24 hours of a physician's first contact with the patient.

Design outcomes

Primary

MeasureTime frameDescription
Severity of illness24 hoursMeasured by serial Sequential Organ Failure Assessment (SOFA) score monitoring

Secondary

MeasureTime frameDescription
Sequential Organ Failure Assessment (SOFA) Score monitoring72 hoursThe organs scored are respiratory, cardiovascular, neurologic, hematologic, renal, and liver. Each organ is scored as 0 (best) to 4 (worse) and the total score is the sum of each component.
Mortality28 days28-day survival rate after admission to hospital
ICU length of stay28 daysLength of stay in the Intensive Care Unit
Quick Sequential Organ Failure Assessment (SOFA) Score greater than 26 hoursMeasured by serial Sequential Organ Failure Assessment (SOFA) score monitoring

Countries

Australia, Canada, Colombia, Netherlands, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026